Cytek Biosciences (CTKB) News Today $3.70 -0.01 (-0.27%) Closing price 04:00 PM EasternExtended Trading$3.70 -0.01 (-0.14%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025April 29 at 5:00 PM | globenewswire.comWhy Cytek Biosciences Should Beat Q1 Earnings ExpectationsApril 28 at 11:14 AM | seekingalpha.comTopline Capital Management LLC Acquires New Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)Topline Capital Management LLC bought a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 236,596 shares of the company's stock, valApril 27, 2025 | marketbeat.comRenaissance Technologies LLC Purchases 251,000 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)Renaissance Technologies LLC grew its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 118.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 462,600 shares of the company's stock after purchasing an additional 251,000 shApril 26, 2025 | marketbeat.comCytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comCytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest UpdateCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 4,530,000 shares, a growth of 18.9% from the March 15th total of 3,810,000 shares. Currently, 3.9% of the shares of the stock are sold short. Based on an average daily volume of 878,800 shares, the days-to-cover ratio is currently 5.2 days.April 23, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)JPMorgan Chase & Co. increased its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 58.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 947,683 shares of the company's stock after buying aApril 20, 2025 | marketbeat.comTrexquant Investment LP Has $1.57 Million Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)Trexquant Investment LP boosted its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 50.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 242,599 shares of the company'sApril 12, 2025 | marketbeat.comWellington Management Group LLP Decreases Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB)Wellington Management Group LLP lowered its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 24.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,517,214 sharApril 12, 2025 | marketbeat.comRaymond James Financial Inc. Buys New Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)Raymond James Financial Inc. purchased a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 117,870 shares of the company's stock, valued at approxiApril 7, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Hits New 52-Week Low - Here's WhyCytek Biosciences (NASDAQ:CTKB) Sets New 12-Month Low - Here's What HappenedApril 4, 2025 | marketbeat.com106,597 Shares in Cytek Biosciences, Inc. (NASDAQ:CTKB) Purchased by Teacher Retirement System of TexasTeacher Retirement System of Texas bought a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 106,597 shares of the company's stock, valued at approximately $6March 31, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Sets New 12-Month Low - Should You Sell?Cytek Biosciences (NASDAQ:CTKB) Hits New 1-Year Low - Time to Sell?March 29, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Trading Up 2.2% - Time to Buy?Cytek Biosciences (NASDAQ:CTKB) Trading 2.2% Higher - Time to Buy?March 22, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Hits New 12-Month Low - Should You Sell?Cytek Biosciences (NASDAQ:CTKB) Sets New 1-Year Low - What's Next?March 21, 2025 | marketbeat.comCytek Biosciences Launches Next-Generation Muse Micro Cell Analyzer to Transform Flow Cytometry AccessibilityMarch 21, 2025 | nasdaq.comCytek Biosciences (NASDAQ:CTKB) Receives "Overweight" Rating from StephensStephens reiterated an "overweight" rating and issued a $6.00 price target on shares of Cytek Biosciences in a research note on Wednesday.March 20, 2025 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Shares Purchased by Royce & Associates LPRoyce & Associates LP lifted its position in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 159.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 470,819 shares of the company's stock after acquiringMarch 20, 2025 | marketbeat.comCytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro SystemMarch 18, 2025 | globenewswire.comGlobeflex Capital L P Purchases Shares of 84,434 Cytek Biosciences, Inc. (NASDAQ:CTKB)Globeflex Capital L P purchased a new stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 84,434 shares of the company's stock, valuedMarch 16, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Sets New 1-Year Low - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Hits New 1-Year Low - Should You Sell?March 13, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Here's WhyMarch 12, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Price Target Lowered to $8.00 at Piper SandlerPiper Sandler decreased their target price on Cytek Biosciences from $8.50 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday.March 5, 2025 | marketbeat.comCytek Biosciences (CTKB) Expected to Announce Quarterly Earnings on WednesdayCytek Biosciences (NASDAQ:CTKB) will be releasing earnings after the market closes on Wednesday, March 12. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666441)March 5, 2025 | marketbeat.comCytek Biosciences price target lowered to $8 from $8.25 at Piper SandlerMarch 4, 2025 | markets.businessinsider.comCytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2024 Earnings Call TranscriptMarch 3, 2025 | msn.comCytek Biosciences (NASDAQ:CTKB) Sets New 52-Week Low - Should You Sell?Cytek Biosciences (NASDAQ:CTKB) Hits New 52-Week Low - What's Next?March 1, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPSCytek Biosciences (NASDAQ:CTKB - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $0.02. Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%.February 28, 2025 | marketbeat.comCytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call TranscriptFebruary 28, 2025 | seekingalpha.comCytek Biosciences sees FY25 revenue $204M-$212M, consensus $216.52MFebruary 27, 2025 | markets.businessinsider.comCytek Biosciences reports Q4 revenue $57.48M, consensus $59.38MFebruary 27, 2025 | markets.businessinsider.comCytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 OutlookFebruary 27, 2025 | globenewswire.comEarnings To Watch: Cytek Biosciences Inc (CTKB) Reports Q4 2024 ResultFebruary 26, 2025 | finance.yahoo.comCytek Biosciences, Inc. (NASDAQ:CTKB) Sees Significant Decline in Short InterestCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 3,170,000 shares, a decrease of 8.6% from the January 15th total of 3,470,000 shares. Approximately 2.7% of the shares of the stock are short sold. Based on an average daily volume of 799,100 shares, the days-to-cover ratio is presently 4.0 days.February 18, 2025 | marketbeat.comCytek BiosciencesFebruary 14, 2025 | forbes.comCytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025February 13, 2025 | globenewswire.comCytek Biosciences (NASDAQ:CTKB) Sees Unusually-High Trading Volume - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Sees Strong Trading Volume - What's Next?February 11, 2025 | marketbeat.comCytek Biosciences to Participate in Upcoming Investor ConferencesFebruary 5, 2025 | globenewswire.comCytek Biosciences (NASDAQ:CTKB) Stock Price Down 4% - Here's WhyCytek Biosciences (NASDAQ:CTKB) Trading Down 4% - Time to Sell?February 4, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Trading Up 5% - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Shares Up 5% - Should You Buy?February 3, 2025 | marketbeat.comCytek Biosciences price target raised to $5.25 from $4.50 at Goldman SachsFebruary 2, 2025 | markets.businessinsider.comGoldman Sachs cuts Cytek Biosciences stock rating to sellJanuary 31, 2025 | msn.comCytek Biosciences downgraded to Sell from Buy at Goldman SachsJanuary 31, 2025 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - What's Next?Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - What's Next?January 31, 2025 | marketbeat.comThe Goldman Sachs Group Downgrades Cytek Biosciences (NASDAQ:CTKB) to SellThe Goldman Sachs Group downgraded Cytek Biosciences from a "buy" rating to a "sell" rating and reduced their target price for the company from $7.00 to $4.50 in a research report on Friday.January 31, 2025 | marketbeat.comPiper Sandler Remains a Buy on Cytek Biosciences (CTKB)January 31, 2025 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Down 5.5% - Here's What HappenedCytek Biosciences (NASDAQ:CTKB) Trading Down 5.5% - Time to Sell?January 29, 2025 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) is largely controlled by institutional shareholders who own 53% of the companyJanuary 27, 2025 | finance.yahoo.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Should You Sell?Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Here's What HappenedJanuary 17, 2025 | marketbeat.comCytek Biosciences sees FY24 revenue $200M-$201M, consensus $204.71MJanuary 16, 2025 | markets.businessinsider.com Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address CTKB Media Mentions By Week CTKB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTKB News Sentiment▼0.850.84▲Average Medical News Sentiment CTKB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTKB Articles This Week▼52▲CTKB Articles Average Week Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 10x Genomics News Transcat News Standard BioTools News EyePoint Pharmaceuticals News Senseonics News Allient News Aehr Test Systems News Quantum-Si News Quanterix News 908 Devices News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTKB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTKB Stock Free CTKB Stock Alerts